参与者信息传单中对参与者数据和生物样本使用的描述不足
该研究对爱尔兰和英国的240份参与者信息传单(PILs,涉及182项临床试验)进行回顾性定性分析,评估试验团队如何描述当前和未来对参与者数据及生物样本的使用。结果显示,多数PILs对数据保密维护、存储期限、未来研究使用和数据共享等描述不足,仅38%被作者认为充分描述了数据保密维护方式。作者提出8个推荐问题供试验团队设计PILs时参考。
要点
- 85%的PILs提及或直接暗示如何维护参与者数据保密性,但仅38%被作者认为充分描述(即明确提及数据去标识化和遵守数据保护法规)。
- 47%的PILs报告了数据存储的预期时长(均值15年,标准差±9年)。
- 在117份声明将采集生物样本的PILs中,80%提供了采集样本的原因,66%说明存储样本是否去标识化,21%说明是否向参与者提供个体结果,70%说明样本是否可能用于未来研究。
核心结论
- PILs对参与者数据当前使用和未来再利用的计划常描述不足,多数未充分描述数据保密维护计划;需要描述数据使用和再利用的最佳实践方法,并需包括潜在试验参与者在内的多方利益相关者参与推进。
研究设计与样本
- 对爱尔兰和英国的240份PILs(涉及182项临床试验)进行回顾性定性分析,采用4阶段实用内容分析法提取和分析数据与样本使用/再利用的描述,并制定推荐问题列表。
主要发现
- 240份PILs中,85%具体提及或直接暗示如何维护参与者数据保密性,38%被作者认为充分描述了数据保密维护方式(即PIL具体提及数据去标识化和遵守数据保护法规),47%报告了数据存储的预期时长(均值15年,标准差±9年),40%说明了数据是否将用于未来研究,28%说明了数据是否将与其他研究人员共享。
- 117份声明将采集生物样本的PILs中,80%提供了请求样本的原因,66%说明存储样本是否去标识化,21%说明是否向参与者提供个体水平结果,70%说明样本是否可能用于未来研究。
- 73份说明计划未来样本存储的PILs中,18%说明了预期存储时长,48%说明样本是否将与其他研究人员共享。
关键数值与推荐
- 识别出8个推荐问题供试验团队设计PILs时参考,例如「当前研究的数据和样本预期存储时长是多少?」。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With greater availability of participant data and biobank repositories following clinical trial completion, adequately describing future data and biological sample reuse plans to trial participants is increasingly important. We evaluated how trial teams currently describe current and future use of participant data and biological samples in participant information leaflets (PILs). METHODS: Retrospective qualitative analysis of 240 PILs (182 clinical trials) in Ireland and the UK. Descriptions of data and sample use/reuse were extracted and analyzed using a 4-stage pragmatic content analysis approach. A recommended list of questions to be addressed by trial teams when designing PILs was developed. RESULTS: Of the 240 included PILs, 85% specifically mentioned, or directly implied, how confidentiality of participant data would be maintained; 38% were considered by the authors to adequately describe how data confidentiality would be maintained (ie, the PIL specifically mentioned data deidentification and compliance with data protection regulations); 47% reported the intended duration of data storage (mean 15; SD ± 9 years); 40% specified if data would be used in future research studies and 28% stated if data would be shared with other researchers. Of the 117 PILs stating biological samples would be collected from participants, 80% provided a reason for requesting the sample, 66% stated whether stored samples would be deidentified, 21% specified if individual-level results would be made available to participants and 70% specified whether samples may be used for future studies. Of the 73 PILs specifying planned future sample storage, 18% stated the intended duration of storage and 48% specified if samples would be shared with other researchers. A list of 8 recommended questions to be addressed by trial teams when designing PILs were identified, for example, 'What is the intended duration of data and sample storage for the current study?'. CONCLUSIONS: PILs often provide insufficient detail regarding plans for current use and future reuse of participants' data and their biological samples. The majority do not adequately describe plans for maintaining data confidentiality. Best practice approaches to describing data use and reuse in PILs are needed. This will require multistakeholder input, including potential trial participants to progress this.
引用
- McGrath ER, Kirby N, Shiely F, et al. Use of participant data and biological samples is insufficiently described in participant information leaflets. J Clin Epidemiol. 2024. PMID: 39505053. doi:10.1016/j.jclinepi.2024.111590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。